GANX · Gain Therapeutics, Inc.
$1.77
-0.08 (-4.32%)
At close · Aug 28
Going-concern doubt
— flagged Aug 11, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Our projected cash outflows for the upcoming periods raise substantial doubt about our ability to continue as a going concern for at least 12 months from the issuance of the financial statements included elsewhere in this Quarterly Report.”View the 10-Q filed Aug 11, 2026
Market Cap
$77.25M
Shares
43.64M
Fails to deliver — shares from a trade that were not delivered to the buyer by the settlement date — published by the SEC twice a month. Persistent fails can reflect settlement problems or naked short selling.
Fails to Deliver History
| Settlement Date | Quantity | Price | Value |
|---|---|---|---|
| 2026-07-31 | 75,488 | $1.76 | $132,859 |
| 2026-07-30 | 62,736 | $1.69 | $106,024 |
| 2026-07-23 | 11,480 | $1.84 | $21,123 |
| 2026-07-22 | 39,647 | $1.84 | $72,950 |
| 2026-07-17 | 2,977 | $1.66 | $4,942 |
| 2026-07-16 | 1,598 | $1.68 | $2,685 |
| 2026-07-15 | 77,643 | $1.68 | $130,440 |
| 2026-07-14 | 6,657 | $1.76 | $11,716 |
| 2026-07-07 | 250 | $1.81 | $453 |
| 2026-07-06 | 60 | $1.91 | $115 |
| 2026-07-02 | 6,196 | $1.99 | $12,330 |
| 2026-07-01 | 36,114 | $2.03 | $73,311 |
| 2026-06-30 | 61,140 | $1.98 | $121,057 |
| 2026-06-25 | 9,439 | $1.74 | $16,424 |
| 2026-06-24 | 36,950 | $1.77 | $65,402 |
| 2026-06-22 | 1,103 | $1.88 | $2,074 |
| 2026-06-18 | 4,722 | $1.78 | $8,405 |
| 2026-06-17 | 8,726 | $1.79 | $15,620 |
| 2026-06-15 | 51,114 | $1.68 | $85,872 |
| 2026-06-11 | 106 | $1.64 | $174 |
| 2026-06-10 | 200,220 | $1.65 | $330,363 |
| 2026-06-09 | 9,452 | $1.69 | $15,974 |
| 2026-06-05 | 7,038 | $1.86 | $13,091 |
| 2026-06-03 | 90,967 | $1.83 | $166,470 |
Showing 1–24 of 24 settlements
Key facts
CIK
1819411
CUSIP
36269B105
13F (30d)
42 filings
42 filers
Visit website
Investor relations